PT1948608E - Novos sais farmacêuticos e polimorfos de um inibidor do fator xa - Google Patents

Novos sais farmacêuticos e polimorfos de um inibidor do fator xa Download PDF

Info

Publication number
PT1948608E
PT1948608E PT06837238T PT06837238T PT1948608E PT 1948608 E PT1948608 E PT 1948608E PT 06837238 T PT06837238 T PT 06837238T PT 06837238 T PT06837238 T PT 06837238T PT 1948608 E PT1948608 E PT 1948608E
Authority
PT
Portugal
Prior art keywords
iminomethyl
polymorphs
benzamide
pyridinyl
dimethylamino
Prior art date
Application number
PT06837238T
Other languages
English (en)
Portuguese (pt)
Inventor
James P Kanter
Craig Grant
Graeme Langlands
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PT1948608E publication Critical patent/PT1948608E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT06837238T 2005-11-08 2006-11-07 Novos sais farmacêuticos e polimorfos de um inibidor do fator xa PT1948608E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73522405P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
PT1948608E true PT1948608E (pt) 2012-05-24

Family

ID=38023988

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06837238T PT1948608E (pt) 2005-11-08 2006-11-07 Novos sais farmacêuticos e polimorfos de um inibidor do fator xa

Country Status (20)

Country Link
US (7) US7598276B2 (cg-RX-API-DMAC7.html)
EP (2) EP2431358A1 (cg-RX-API-DMAC7.html)
JP (2) JP5227178B2 (cg-RX-API-DMAC7.html)
KR (1) KR101358574B1 (cg-RX-API-DMAC7.html)
CN (2) CN102336702B (cg-RX-API-DMAC7.html)
AR (2) AR056787A1 (cg-RX-API-DMAC7.html)
AT (1) ATE549317T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006311544B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618362A2 (cg-RX-API-DMAC7.html)
CA (1) CA2627086C (cg-RX-API-DMAC7.html)
DK (1) DK1948608T3 (cg-RX-API-DMAC7.html)
ES (1) ES2384116T3 (cg-RX-API-DMAC7.html)
IL (2) IL190524A (cg-RX-API-DMAC7.html)
NZ (2) NZ592533A (cg-RX-API-DMAC7.html)
PE (2) PE20070717A1 (cg-RX-API-DMAC7.html)
PT (1) PT1948608E (cg-RX-API-DMAC7.html)
RU (1) RU2440986C2 (cg-RX-API-DMAC7.html)
TW (1) TWI443088B (cg-RX-API-DMAC7.html)
WO (1) WO2007056517A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200803820B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311366T1 (de) * 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CA2565437A1 (en) * 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
PT2404906E (pt) 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
PT2101760E (pt) * 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
EP2155195B1 (en) * 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
NZ581324A (en) 2007-05-02 2012-05-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
LT3604510T (lt) 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5766204B2 (ja) 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
US8530501B2 (en) * 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
TW201221128A (en) * 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
WO2013033370A1 (en) 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) * 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
KR20250150675A (ko) 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
CN108883160B (zh) 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
CN116425860B (zh) 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN108017576B (zh) * 2016-11-01 2022-06-21 石药集团中奇制药技术（石家庄）有限公司 一种贝曲西班及其盐酸盐的制备方法，以及它们的晶型
CN108586325A (zh) * 2017-03-16 2018-09-28 上海度德医药科技有限公司 一种Betrixaban中间体的制备方法
WO2018229796A2 (en) * 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177752T1 (de) 1992-12-15 1999-04-15 Corvas Int Inc Neue inhibitoren von faktor xa
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
PT798295E (pt) 1994-12-02 2003-07-31 Yamanouchi Pharma Co Ltd Novo derivado de amidinonaftilo ou sal deste
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
KR20010023364A (ko) 1997-08-27 2001-03-26 간자와 무츠와 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
HK1052497B (zh) * 1999-09-17 2007-03-02 千禧药品公司 苯甲酸胺和相关的因子xa抑制剂
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
PT2404906E (pt) 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa

Also Published As

Publication number Publication date
CN102336702B (zh) 2015-02-11
EP2431358A1 (en) 2012-03-21
AR056787A1 (es) 2007-10-24
US7598276B2 (en) 2009-10-06
BRPI0618362A2 (pt) 2011-08-30
DK1948608T3 (da) 2012-07-02
KR20080065662A (ko) 2008-07-14
RU2008123055A (ru) 2009-12-20
JP5662980B2 (ja) 2015-02-04
TW200736221A (en) 2007-10-01
EP1948608A2 (en) 2008-07-30
IL190524A0 (en) 2008-12-29
IL213487A0 (en) 2011-07-31
AR106960A2 (es) 2018-03-07
NZ567992A (en) 2011-05-27
US8557852B2 (en) 2013-10-15
TWI443088B (zh) 2014-07-01
HK1115131A1 (en) 2008-11-21
IL190524A (en) 2013-02-28
WO2007056517A2 (en) 2007-05-18
EP1948608B1 (en) 2012-03-14
RU2440986C2 (ru) 2012-01-27
US9061019B2 (en) 2015-06-23
PE20070717A1 (es) 2007-08-17
KR101358574B1 (ko) 2014-02-04
PE20110070A1 (es) 2011-03-04
CN101304971A (zh) 2008-11-12
US20070112039A1 (en) 2007-05-17
ES2384116T3 (es) 2012-06-29
ZA200803820B (en) 2009-03-25
JP2012246323A (ja) 2012-12-13
CA2627086A1 (en) 2007-05-18
AU2006311544A1 (en) 2007-05-18
CA2627086C (en) 2016-04-05
JP5227178B2 (ja) 2013-07-03
ATE549317T1 (de) 2012-03-15
US20170326119A1 (en) 2017-11-16
AU2006311544B2 (en) 2012-03-08
WO2007056517A3 (en) 2008-04-17
US20140288028A1 (en) 2014-09-25
CN102336702A (zh) 2012-02-01
US20160101089A1 (en) 2016-04-14
CN101304971B (zh) 2011-09-07
US20190046510A1 (en) 2019-02-14
US9555023B2 (en) 2017-01-31
NZ592533A (en) 2012-08-31
US20130064806A1 (en) 2013-03-14
US20100063113A1 (en) 2010-03-11
JP2009514976A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
ZA200803820B (en) Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino) iminomethyl] benzoyl] amino]-5-meth oxy-benzamide, A factor Xa inhibitor
FIC20210010I1 (fi) Fedratinibi tai sen farmaseuttisesti hyväksyttävä suola tai sen farmaseuttisesti hyväksyttävä hydraatti, erityisesti fedratinibidihydrokloridimonohydraatti
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
DK1589005T3 (da) Fremgangsmåde til syntese af ivabradin og additionssalte heraf med en farmaceutisk acceptabel syre
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
EP2024341A4 (en) NEW PROCEDURES FOR STATINE AND THEIR PHARMACEUTICALLY UNINTENTIONAL SALTS
AP1956A (en) y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it
ZA200801351B (en) Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
IL186308A (en) A pharmaceutical composition containing metformin hydrochloride and pioglitazone hydrochloride
IL200561A (en) Heterocyclic inhibitors of aspartate protease or their tautomers, their acceptable pharmacy salt, their pharmacy composition and their use
PL2322180T3 (pl) Sole diketopiperazyny do dostarczania leków
PL1807057T3 (pl) Sole polimerów amin alifatycznych do tabletkowania
IL225167A (en) Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
DK1614687T3 (da) Fremgangsmåde til fremstilling af 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onderivater og deres anvendelse ved syntese af ivabradin og farmaceutisk acceptable salte deraf
WO2006090268A3 (en) Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
DK1848419T3 (da) Injektionspræparater med diclofenac og farmaceutisk acceptable salte deraf
DK1589014T3 (da) Fremgangsmåde til syntese af derivater af 1,3-dihydro-2H-3-benzazepin-2-on og anvendelse heraf ved syntese af ivabradin og additionssalte heraf med en farmaceutisk acceptabel syre
EP1900735A4 (en) PYRIDAZINYLAMINE DERIVATIVES, USE OF DERIVATIVES IN THE PREPARATION OF PICORNAVIRUS INHIBITORS
EP1878719A4 (en) HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL
EP1795526A4 (en) N-SUBSTITUTED N- (4-PIPERIDINYL) AMIDE DERIVATIVE
ZA200708494B (en) 4-(pyrid-2-yl) amino substituted pyrimidime as protein kinase inhibitors
HK1105644A (en) Polymorph of n,n-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt